Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport—an update
Q Mao, JD Unadkat - The AAPS journal, 2015 - Springer
The human breast cancer resistance protein (BCRP, gene symbol ABCG2) is an ATP-
binding cassette (ABC) efflux transporter. It was so named because it was initially cloned …
binding cassette (ABC) efflux transporter. It was so named because it was initially cloned …
Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia
M Miura - Biological and Pharmaceutical Bulletin, 2015 - jstage.jst.go.jp
Imatinib, nilotinib, and dasatinib are tyrosine kinase inhibitors (TKIs) that have become first-
line treatments for Philadelphia chromosome-positive chronic myeloid leukemia (CML) …
line treatments for Philadelphia chromosome-positive chronic myeloid leukemia (CML) …
[HTML][HTML] Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates
M Saiz-Rodríguez, S Almenara, M Navares-Gómez… - Biomedicines, 2020 - mdpi.com
Several cytochrome P450 (CYP) CYP3A polymorphisms were associated with reduced
enzyme function. We aimed to evaluate the influence of these alleles on the …
enzyme function. We aimed to evaluate the influence of these alleles on the …
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?
H Bruckmueller, I Cascorbi - Expert opinion on drug metabolism & …, 2021 - Taylor & Francis
Introduction Interindividual differences in drug response are a frequent clinical challenge
partly due to variation in pharmacokinetics. ATP-binding cassette (ABC) transporters are …
partly due to variation in pharmacokinetics. ATP-binding cassette (ABC) transporters are …
Activation/inactivation of anticancer drugs by CYP3A4: influencing factors for personalized cancer therapy
F Wang, X Zhang, Y Wang, Y Chen, H Lu… - Drug Metabolism and …, 2023 - ASPET
Cytochrome P450 3A4 (CYP3A4), one of the most important members of the cytochrome
P450 subfamily, is a crucial catalyst in the metabolism of numerous drugs. As it catalyzes …
P450 subfamily, is a crucial catalyst in the metabolism of numerous drugs. As it catalyzes …
BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications
D Hira, T Terada - Biochemical Pharmacology, 2018 - Elsevier
The human breast cancer resistance protein (BCRP/ABCG2) is an ATP-binding cassette
efflux transporter that uses ATP hydrolysis to expel xenobiotics from cells, including anti …
efflux transporter that uses ATP hydrolysis to expel xenobiotics from cells, including anti …
Impact of membrane drug transporters on resistance to small-molecule tyrosine kinase inhibitors
C Neul, E Schaeffeler, A Sparreboom, S Laufer… - Trends in …, 2016 - cell.com
Small-molecule inhibitors of tyrosine kinases (TKIs) are the mainstay of treatment for many
malignancies and represent novel treatment options for other diseases such as idiopathic …
malignancies and represent novel treatment options for other diseases such as idiopathic …
Polymorphisms of the multidrug pump ABCG2: a systematic review of their effect on protein expression, function, and drug pharmacokinetics
N Heyes, P Kapoor, ID Kerr - Drug Metabolism and Disposition, 2018 - ASPET
The widespread expression and polyspecificity of the multidrug ABCG2 efflux transporter
make it an important determinant of the pharmacokinetics of a variety of substrate drugs. Null …
make it an important determinant of the pharmacokinetics of a variety of substrate drugs. Null …
Individualized dosing of tyrosine kinase inhibitors: are we there yet?
D de Wit, HJ Guchelaar, J den Hartigh… - Drug discovery today, 2015 - Elsevier
Highlights•Complete overview on exposure–response relationships for TKIs used in solid
tumors.•Dose individualization is expected to minimize toxicity and improve efficacy.•For …
tumors.•Dose individualization is expected to minimize toxicity and improve efficacy.•For …
[HTML][HTML] Genotypes affecting the pharmacokinetics of anticancer drugs
D Bertholee, JG Maring, ABP van Kuilenburg - Clinical pharmacokinetics, 2017 - Springer
Cancer treatment is becoming more and more individually based as a result of the large
inter-individual differences that exist in treatment outcome and toxicity when patients are …
inter-individual differences that exist in treatment outcome and toxicity when patients are …